Proud to see our research being presented at #ASCO2026 as we continue our mission to transform cancer care through innovative blood-based testing.
We welcome the opportunity to connect with colleagues, collaborators, and new partners throughout #ASCO26.
#LiquidBiopsy#Adela
We're excited to announce two presentations at #ASCO25 demonstrating the ability of Adela's tissue-agnostic test for MRD Detection and Response Monitoring to predict progression and identify non-responders to immunotherapy in solid tumors.
https://t.co/WrZxxLCk5T
Looking forward to engaging with the oncology community on how #liquidbiopsy and tissue-free approaches are advancing cancer detection and monitoring across the cancer continuum #ASCO26
If you’re attending, let’s connect.
#Oncology#Adela@ASCO@ConquerCancerFd@OncUpdates
Heading to Precision Med #TRICON in San Diego? Catch Partner Mara Aspinall at two key sessions:
📅 3/11 | 3:40 PM PT – Driving Innovation in Precision Medicine
📅 3/12 | 8:00 AM PT – Investing in Precision Medicine
More info: https://t.co/4SHO3e57pU
@TriConference
Heading to Precision Med #TRICON in San Diego? Catch Partner Mara Aspinall at two key sessions:
📅 3/11 | 3:40 PM PT – Driving Innovation in Precision Medicine
📅 3/12 | 8:00 AM PT – Investing in Precision Medicine
More info: https://t.co/4SHO3e57pU
@TriConference
Jensen Huang, speaking at PMWC to a room full of healthcare pioneers, “Biology is one of the hardest problems. I’ve always hoped that your industry would have the benefit of our industry.”
“Artificial intelligence is finding intelligence in the data that you have.”
Adela demonstrates in a clinical validation study published in The Annals of Oncology the ability to detect recurrence up to 15 months in advance of clinical presentation (mean 4.1 months). Detecting early relapse can contribute to improved outcomes by guiding early intervention.
Today we are celebrating a significant milestone for Adela: the simultaneous publication of our clinical validation study for our tissue-agnostic MRD test in Head & Neck cancer in @Annals_Oncology and its presentation at #ESMO24.
https://t.co/90Yscac7FQ
Exciting presentation at ESMO demonstrating Adela's ability to detect recurrence in Head & Neck Cancer patients up to 15 months in advance of imaging/clinical presentation with a mean lead time of 4.1 months. #precisiononcology
Adela is presenting at #AACR2024! Highlights include data in head & neck cancer from our tissue-agnostic MRD assay, and Chief Scientific Officer @decarvalho_lab chairing the Plenary Session “Discovery Science in Early Cancer Biology and Interception”.
https://t.co/lt5Odw3nkI
Adela will be presenting data at #ESMO23 demonstrating strong prognostic prediction capabilities of our genome-wide methylome enrichment platform in Head and Neck Cancer and Renal Cell Carcinoma
https://t.co/MjNLsdhS6x
Thank you @SliceofHC - "Adela is poised to make significant strides in the realm of early cancer detection and MRD monitoring" https://t.co/dJzMfrVbcR
#precisionmedicine
I'm excited to share ep. 1 of Closing Time is live! Tune in as @LisaA pitches her new startup to @Lux_Capital General Partner @deenashakir. Co-hosted with my longtime friend @halletecco, Closing Time gives a unique view into the exciting world of healthcare startups.